INAL RESEARCH Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study

被引:5
|
作者
Kang, D. -W. [1 ]
Park, S. -K. [2 ]
Yu, Y. L. [3 ]
Lee, Y. [4 ]
Lee, D. H. [5 ]
Kang, S. [3 ,6 ,7 ,8 ]
机构
[1] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea
[2] Catholic Univ Korea, Coll Pharm, Bucheon, South Korea
[3] Natl Canc Ctr, Ctr Gynecol Canc, Res Inst & Hosp, Goyang, South Korea
[4] Natl Canc Ctr, Dept Internal Med, Goyang, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[6] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Control & Policy, Goyang, South Korea
[7] Natl Canc Ctr, Res Inst & Hosp, Ctr Gynecol Canc, 323 Ilsan Ro, Goyang Si, Gyeonggi Do, South Korea
[8] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Control & Policy, 323 Ilsan Ro, Goyang Si, Gyeonggi Do, South Korea
关键词
next-generation sequencing; single-gene testing; non-small-cell lung cancer; distant metastasis; real-world evidence;
D O I
10.1016/j.esmoop.2023.102200
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Despite the growing use of next-generation sequencing (NGS) in the management of advanced non-smallcell lung cancer (NSCLC), there is little evidence that its use leads to improved clinical outcomes. This study aimed to compare the effectiveness of NGS with that of single-gene testing (SGT) alone in patients with advanced NSCLC. Materials and methods: This was a retrospective cohort study conducted on patients diagnosed with advanced lung adenocarcinoma between 2017 and 2018 from a nationwide, population-based database. We identified patients who had SGT exclusively (SGT group) or underwent upfront NGS or NGS following SGT as an initial evaluation (NGS group). Patients were followed up until death or the end of the study (31 December 2019). The adjusted hazard ratio (aHR) for death was estimated using the Cox proportional hazards model. The factors affecting the adoption of NGS were identified. Results: Of 8566 patients diagnosed with advanced lung adenocarcinoma, 402 and 6932 patients were assigned to the NGS and SGT groups, respectively. More NGS was carried out in younger patients, those with higher incomes, and those living in urban areas. After balancing these confounders through matching, no difference was observed in the median overall survival and risk of death between the NGS and SGT groups [18.5 versus 19.7 months, log-rank P 1/4 0.783; aHR 0.98, 95% confidence interval (CI) 0.84-1.14, respectively]. Only in a subgroup for whom epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) inhibitors were not indicated, NGS was associated with better survival outcomes (14.1 versus 9.0 months, log-rank P 1/4 0.006; aHR 0.82, 95% CI 0.69-0.97). Conclusions: In the real world, NGS for all-comers in patients with advanced NSCLC did not increase survival outcomes. When health care resources to support equal access to NGS are limited, upfront SGT followed by NGS may be a more efficient strategy
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer
    Ying-Qiang Lu
    Kai-Hua Lu
    慢性疾病与转化医学(英文), 2017, 3 (01) : 1 - 7
  • [2] Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients
    Ulivi, Paola
    Urbini, Milena
    Petracci, Elisabetta
    Canale, Matteo
    Dubini, Alessandra
    Bartolini, Daniela
    Calistri, Daniele
    Cravero, Paola
    Fonzi, Eugenio
    Martinelli, Giovanni
    Priano, Ilaria
    Andrikou, Kalliopi
    Bronte, Giuseppe
    Crino, Lucio
    Delmonte, Angelo
    CANCERS, 2022, 14 (10)
  • [3] Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer.
    Presley, Carolyn Jean
    Soulos, Pamela R.
    Chiang, Anne C.
    Longtine, Janina A.
    Adelson, Kerin B.
    Herbst, Roy S.
    Nussbaum, Nathan C.
    Sorg, Rachael
    Abernethy, Amy Pickar
    Agarwala, Vineeta
    Gross, Cary Philip
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Clinical Next-Generation Sequencing in Patients with Non-Small Cell Lung Cancer
    Hagemann, Ian S.
    Devarakonda, Siddhartha
    Lockwood, Christina M.
    Spencer, David H.
    Guebert, Kalin
    Bredemeyer, Andrew J.
    Al-Kateb, Hussam
    Nguyen, TuDung T.
    Duncavage, Eric J.
    Cottrell, Catherine E.
    Kulkarni, Shashikant
    Nagarajan, Rakesh
    Seibert, Karen
    Baggstrom, Maria
    Waqar, Saiama N.
    Pfeifer, John D.
    Morgensztern, Daniel
    Govindan, Ramaswamy
    CANCER, 2015, 121 (04) : 631 - 639
  • [5] Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients
    Nie, Keke
    Jiang, Haiping
    Zhang, Chunling
    Geng, Chuanxin
    Xu, Xiajuan
    Zhang, Ling
    Zhang, Hao
    Zhang, Zhongfa
    Lan, Ketao
    Ji, Youxin
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [6] Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients
    Takeyasu, Yuki
    Yoshida, Tatsuya
    Motoi, Noriko
    Teishikata, Takashi
    Tanaka, Midori
    Matsumoto, Yuji
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Kakishima, Hiroki
    Tsuchida, Takaaki
    Yamamoto, Noboru
    Ohe, Yuichiro
    Yatabe, Yasushi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (07) : 1114 - 1122
  • [7] Next generation sequencing in non-small-cell lung cancer patients from northwestern Spain
    Sanchez Ares, M.
    Perez-Becerra Ferreiro, R.
    Antunez Lopez, J. R.
    Couso Folgueira, E.
    Rico Rodriguez, T. Y.
    Vazquez Boquete, A.
    Cameselle Teijeiro, J. M.
    Abdulkader Nallib, I.
    VIRCHOWS ARCHIV, 2018, 473 : S115 - S116
  • [8] Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing-Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non-Small-Cell Lung Cancer in the United States
    Zou, Denise
    Ye, Weicheng
    Hess, Lisa M.
    Bhandari, Naleen Raj
    Ale-Ali, Amine
    Foster, Jacinda
    Quon, Peter
    Harris, Mack
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (08): : 901 - 914
  • [9] The rational application of liquid biopsy based on next-generation sequencing in advanced non-small cell lung cancer
    Zhao, Chenglong
    Li, Jianghua
    Zhang, Yongchang
    Han, Rui
    Wang, Yubo
    Li, Li
    Zhang, Yimin
    Zhu, Mengxiao
    Zheng, Jie
    Du, Haiwei
    Hu, Chen
    Zhou, Chengzhi
    Yang, Nong
    Cai, Shangli
    He, Yong
    CANCER MEDICINE, 2023, 12 (05): : 5603 - 5614
  • [10] Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer
    Steuten, Lotte
    Goulart, Bernardo
    Meropol, Neal J.
    Pritchard, Daryl
    Ramsey, Scott D.
    JCO CLINICAL CANCER INFORMATICS, 2019, 3 : 1 - 10